World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
108
Citations
56040
World Ranking
5908
National Ranking
3167

Overview

Kevin L. Winthrop is affiliated with Oregon Health & Science University in the United States. Their research primarily focuses on a range of topics within medicine, with a specialization in rheumatology, epidemiology, infectious diseases, immunology, and hematology.

Their work centers on key topics including:

  • Rheumatoid Arthritis Research and Therapies
  • Mycobacterium research and diagnosis
  • Tuberculosis Research and Epidemiology
  • Autoimmune and Inflammatory Disorders Research
  • Systemic Lupus Erythematosus Research
  • Chronic Lymphocytic Leukemia Research
  • Psoriasis: Treatment and Pathogenesis

Kevin L. Winthrop has contributed to publications in a diverse range of high-impact venues, frequently publishing in:

  • Annals of the Rheumatic Diseases
  • CHEST Journal
  • Arthritis & Rheumatology
  • Open Forum Infectious Diseases
  • RMD Open

Their recent papers include:

  • EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update (2022, Annals of the Rheumatic Diseases)
  • Neutralizing monoclonal antibodies for treatment of COVID-19 (2021, Nature reviews. Immunology)
  • Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline (2020, European Respiratory Journal)
  • Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline (2020, Clinical Infectious Diseases)

Frequent co-authors collaborating with Kevin L. Winthrop include:

  • Gerd R Burmester
  • Yoshiya Tanaka
  • Jeffrey R. Curtis
  • Tsutomu Takeuchi
  • Daniel Aletaha

Kevin L. Winthrop's work spans multiple subfields of medicine, demonstrating expertise in rheumatology, epidemiology, infectious diseases, immunology, and hematology. Their publications contribute to ongoing research and treatment strategies related to autoimmune and inflammatory disorders, infectious pulmonary diseases, and hematologic conditions.

Best Publications

  • An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.

    David E. Griffith;Timothy Aksamit;Barbara A. Brown-Elliott;Antonino Catanzaro

  • EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

    Josef S Smolen;Robert Landewé;Ferdinand C Breedveld;Maya Buch;Maya Buch

  • 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

    Jasvinder A. Singh;Daniel E. Furst;Aseem Bharat;Jeffrey R. Curtis

  • Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline

    Charles L. Daley;Jonathan M. Iaccarino;Christoph Lange;Emmanuelle Cambau

  • Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010

    D. E. Furst;E. C. Keystone;J. Braun;F. C. Breedveld

  • Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA)

    Maxime Dougados;Martin Soubrier;Anna Antunez;Peter Balint

  • The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study

    Wouter Hoefsloot;Jakko Van Ingen;Claire Andrejak;Kristian Ängeby

  • Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis

    Sofia Ramiro;Cécile Gaujoux-Viala;Jackie L Nam;Jackie L Nam;Josef S Smolen

  • Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline: Executive Summary

    Charles L Daley;Jonathan M Iaccarino;Christoph Lange;Emmanuelle Cambau

  • Neutralizing monoclonal antibodies for treatment of COVID-19.

    Peter C. Taylor;Andrew C. Adams;Matthew M. Hufford;Inmaculada de la Torre

  • Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force

    Josef S. Smolen;Jürgen Braun;Maxime Dougados;Paul Emery

  • The emerging safety profile of JAK inhibitors in rheumatic disease

    Kevin L. Winthrop

  • European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies

    L Gossec;J S Smolen;C Gaujoux-Viala;Z Ash

  • US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis

    R. Andres Floto;R. Andres Floto;Kenneth N. Olivier;Lisa Saiman;Charles L. Daley

  • Pulmonary Nontuberculous Mycobacterial Disease Prevalence and Clinical Features An Emerging Public Health Disease

    Kevin L. Winthrop;Erin McNelley;Brian Kendall;Allison Marshall-Olson

  • Nontuberculous mycobacterial disease prevalence and risk factors: a changing epidemiology.

    P. Maureen Cassidy;Katrina Hedberg;Ashlen Saulson;Erin McNelly

  • Infection Risk and Safety of Corticosteroid Use

    Jameel Youssef;Shannon A. Novosad;Kevin L. Winthrop

  • The role of IL-6 in host defence against infections: immunobiology and clinical implications

    Stefan Rose-John;Kevin Winthrop;Leonard Calabrese

  • Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA

    J. L. Nam;K. L. Winthrop;R. F. Van Vollenhoven;K. Pavelka

  • Erratum: The emerging safety profile of JAK inhibitors in rheumatic disease

    Kevin L. Winthrop

Frequent Co-Authors

Jeffrey R. Curtis
Jeffrey R. Curtis University of Alabama at Birmingham
John W. Baddley
John W. Baddley University of Alabama at Birmingham
Charles L. Daley
Charles L. Daley National Jewish Health
Kenneth G. Saag
Kenneth G. Saag University of Alabama at Birmingham
Josef S. Smolen
Josef S. Smolen Medical University of Vienna
Kenneth N. Olivier
Kenneth N. Olivier National Institutes of Health
Mark C. Genovese
Mark C. Genovese Stanford University
Yoshiya Tanaka
Yoshiya Tanaka University of Occupational and Environmental Health Japan
Paul Emery
Paul Emery University of Leeds
Maxime Dougados
Maxime Dougados Hôpital Cochin

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine opens doors to a wide range of related healthcare degrees and pathways. For registered nurses looking to advance their skills, rn to fnp bridge programs provide an efficient route to become a Family Nurse Practitioner through flexible online study.

If you’re interested in nutrition and its impact on health, the best online food science degree programs can prepare you for careers in dietetics, research, or healthcare consulting. These online options allow you to balance education with work or other commitments.

Leadership roles in hospitals and clinics often require specialized education in administration. It’s important to seek which online healthcare administration programs have cahme accreditation? CAHME accreditation ensures the highest standards in healthcare management education, increasing your employment prospects in the field.

For nurses seeking advancement without additional clinical hours, consider rn to bsn programs without clinicals. These programs deliver key theoretical knowledge online and help you upgrade your credentials while accommodating busy schedules.

Best Scientists Citing Kevin L. Winthrop

Trending Scientists